



# THE PROBLEM

**20%**

of **diabetic** patients develop  
a **wound that does not heal**.

**Every 20 seconds**  
someone **loses a limb**.


**Current treatments are expensive** and  
do not reduce amputation rates.

120 million diabetics with  
ulcers today **need more**  
**effective and accessible**  
**solutions**.

# OUR SOLUTION

## TRV-01

A genetically modified **skin**  
**substitute** designed specifically  
to treat diabetic foot ulcers.



**Heals like healthy skin.**



- **Increases blood flow.**
- **Promotes cellular regeneration.**

# DEVELOPMENT STAGE



**TRL level 5**


TRV-01 has been tested in chronic  
diabetic models, demonstrating  
its efficacy for rapid and effective  
wound healing.



**Intellectual  
Property**



# FOUNDING TEAM



**Blanca Segura**  
PhD, CEO  
Gene and cell  
therapy expert.  
Inventor of  
multiple  
medical  
methods and  
devices.





**Ian Wisenberg**  
Expertise in  
international  
business,  
corporate  
development,  
and financing.



**Rodrigo González**  
Biotechnology  
expert. Development  
of whole-cell  
therapeutic cancer  
vaccines. Process  
development and  
GMP manufacturing.

# MERCADO

The global diabetic foot treatment market is estimated  
at \$8.9 billion (CAGR 6.3%).



# INVESTMENT

Series A Fundraising

**USD 5.49 millions**

Funding the cash deficit for the growth  
plan over the next **18 months** of operations.

Phase I - II Study

Strengthening the Commercial  
Team and Marketing

ActivitiesWorking Capital (OPEX)

In the next **18 months**

**1**

› Obtaining results from Phase Ib  
and IIa studies

**2**

› Production and  
commercial GMP scaling

**3**

› Submission of the  
dossier to the FDA (IND)

**Contact:**

Francisco Lozano Martínez  
[flozano@newgenesis.cl](mailto:flozano@newgenesis.cl)

Raúl Vázquez Cassani  
[rvazquez@newgenesis.cl](mailto:rvazquez@newgenesis.cl)